Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Psoriasis. Treatment].

C Chiaverini1, F Desruelles, J P Lacour

  • 1Service de Dermatologie, Hôpital de l'Archet 2, Nice.

Presse Medicale (Paris, France : 1983)
|July 27, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of persistent hypogammaglobulinaemia in children with autoimmune bullous dermatoses treated with rituximab.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Management of Tinea Capitis in children under 10 kg : Results from a French multicentre study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Gynaeco-obstetrical follow-up of patients with dystrophic epidermolysis bullosa, a prospective study.

Orphanet journal of rare diseases·2025
Same author

The ink-stain dermoscopic sign as a marker of follicular involvement of congenital nevus of the scalp.

Annales de dermatologie et de venereologie·2024
Same author

French national protocol for the management of congenital ichthyosis.

Annales de dermatologie et de venereologie·2024
Same author

Perception of Oral Health-Related Quality of Life in Children with Epidermolysis Bullosa: A Quantitative and Qualitative Study.

JDR clinical and translational research·2022
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Psoriasis treatment focuses on symptom relief and managing flare-ups, not a cure. A two-phase approach, starting with local care and progressing to systemic treatments if needed, balances benefits and risks for patients.

Area of Science:

  • Dermatology
  • Immunology

Context:

  • Psoriasis management requires a patient-centered approach.
  • No definitive cure exists; treatment aims for symptomatic relief and improved quality of life.

Purpose:

  • To outline a two-phase treatment strategy for psoriasis.
  • To differentiate between local and systemic treatment options.
  • To emphasize the importance of balancing treatment benefits and risks.

Summary:

  • Phase one focuses on inducing remission of active lesions.
  • Phase two aims to prevent future psoriasis flare-ups.
  • Local treatments (keratolytics, corticosteroids, vitamin D3) are preferred for limited lesions.
  • Systemic treatments (phototherapy, retinoids, methotrexate, cyclosporine) are reserved for extensive or refractory cases.

Related Experiment Videos

Impact:

  • Informs clinical decision-making for psoriasis management.
  • Highlights the role of patient education and the therapeutic relationship.
  • Guides the selection of appropriate treatments based on disease severity and patient factors.